Andrew Kolodziej, MD
Advanced Heart Failure and Transplant Cardiology · Lexington, KYNPI 1750519369
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,487 of the $6,836 with a category attached, or 65.6%. 16 manufacturers reported payments, led by Novartis at 33.8% of the total. Reporting peaked in 2020 at $2,506 and has fallen 71.1% since, to $725 in 2025.
Across 107 payments — averaging $63.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Abbott$2K
- United Therapeutics Corporation$626
- Actelion Pharmaceuticals US, Inc.$444
- Cvrx, Inc.$404
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$282
- plus $727 from 10 others
Across 29 payments — averaging $4043.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nuwellis, Inc.$81K
- Abbott$28K
- United Therapeutics Corporation$8K
What the payments were for
- Consulting fees$2,31034%
- Food & beverage$4,48766%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $2,310 |
| Abbott | 67 | $2,043 |
| United Therapeutics Corporation | 8 | $626 |
| Actelion Pharmaceuticals US, Inc. | 4 | $444 |
| Cvrx, Inc. | 7 | $404 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $282 |
| Abiomed | 2 | $255 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Nuwellis, Inc. | 5 | $118 |
| Medtronic | 1 | $114 |
| Prytime Medical Devices, Inc. | 1 | $32 |
| Merck | 1 | $22 |
| AstraZeneca | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$2,310
- CARDIOMEMS$412
- UPTRAVI$372
- Barostim Neo System$260
- OPSUMIT$255
- Impella$255
- CardioMEMS HF System$250
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$181
- CAMZYOS$125
- Mitra Clip system$114
- HeartWare HVAD$114
How this compares
Too few advanced heart failure and transplant cardiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 118 | $3,096,609 |
| Tyvaso DpiTreprostinil | 109 | $2,615,621 |
| OpsumitMacitentan | 158 | $1,977,602 |
| VyndamaxTafamidis | 86 | $1,766,672 |
| AdempasRiociguat | 81 | $1,045,949 |
| WinrevairSotatercept-Csrk | 39 | $808,609 |
| Ambrisentan | 151 | $519,593 |
| EntrestoSacubitril/Valsartan | 459 | $455,624 |
| Orenitram ErTreprostinil Diolamine | 51 | $328,758 |
| JardianceEmpagliflozin | 168 | $188,758 |
| EliquisApixaban | 213 | $161,891 |
| RemodulinTreprostinil Sodium | 38 | $113,067 |
| FarxigaDapagliflozin Propanediol | 72 | $77,095 |
| Tadalafil | 78 | $50,483 |
| Sildenafil Citrate | 257 | $49,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $444 | $5,074,211276 claims |
| BayerAdempas | $15 | $1,045,94981 claims |
| MerckWinrevair | $22 | $808,60939 claims |
| NovartisEntresto | $2,310 | $455,624459 claims |
| United Therapeutics CorporationRemodulin | $626 | $113,06738 claims |
| AstraZenecaFarxiga, Brilinta | $19 | $88,69486 claims |
| Johnson & JohnsonXarelto | $11 | $23,17428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Lexington
- Sonu AbrahamLexington$13K
- Marciano LeeLexington$11K
- Navin RajagopalanLexington$6K
- Maya IgnaszewskiLexington$6K
- Paul AnayaLexington$194
- Timothy RaymondFt Wright$88K
- Chioma ObiokoyeLouisville$14K
- Hareeprasad VongooruEdgewood$8K
- Amaninderapal GhotraEdgewood$8K
- Keerthy NarisettyEdgewood$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.